Arkolith/Insider Trading/VRTX/Form 4

Bunnage Mark E.

EVP, Chief Scientific OfficerVERTEX PHARMACEUTICALS INC / MA (VRTX) · full profile →Form 4 · filed Feb 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$302K
Net Open-Market Flow
-$302K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 25, 2026Sell(S)620$486.35$302K7K
Feb 24, 2026Tax withholding(F)582$485.11$282K8K

Transaction Codes

S
Open-market sale
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000875320-26-000112) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML